Trial Profile
A randomized, double blind, placebo-controlled, crossover, proof of concept study to evaluate the effectiveness and safety of carisbamate in the treatment of essential tremor.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2018
Price :
$35
*
At a glance
- Drugs Carisbamate (Primary)
- Indications Essential tremor
- Focus Therapeutic Use
- Sponsors Ortho-McNeil; SK Life Science
- 01 Aug 2012 Company (SK Life Science) added as an association and lead centre as reported by ClinicalTrials.gov record.
- 03 Mar 2010 Results published in Movement Disorders.
- 29 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.